Clinical Trial

Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer

Name: Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer — clinical trial record (NCT07153770)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study aim to evaluate the efficacy and safety of Bozitinib combined with chemotherapy as radical treatment for stage IIA-IIIC MET-altered non-small cell lung cancer

Trial Details

NCT Number	NCT07153770
Lead Sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Conditions	NSCLC, MET Exon 14 Mutation, MET Activating Mutation
Enrollment	34 participants
Start Date	2025-09-20
Primary Completion	2027-09-20 (estimated)
Study Completion	2028-09-20 (estimated)
Updated on ClinicalTrials.gov	2025-09-04